Healthcare platform Signify Health is offering expanded in-home diagnostic services to Medicare Advantage members. The new offering will support early detection, diagnosis and management of diseases including chronic obstructive pulmonary disease (COPD), peripheral arterial disease, colorectal cancer, chronic kidney disease, diabetes and low-bone density.
“Early diagnosis and management of chronic conditions are critical to achieving better health outcomes and reducing the total cost of care,” Signify Health Chief Medical Officer Marc Rothman, MD, said in a statement. “At Signify, we are performing diagnostic tests in the home to reduce barriers to timely diagnosis and treatment decisions by individuals and their physicians.”
Signify Health began offering spirometry testing to detect COPD in select markets earlier this year. COPD is the fourth leading cause of death in the United States, according to the Centers for Disease Control and Prevention. Nearly 15.7 million Americans have been diagnosed with COPD, however, the CDC said that number could be higher since more than 50% of adults with low pulmonary function were not aware that they might have COPD.
Signify Health uses advanced analytics to identify plan members with gaps in care and connects them with the appropriate diagnostic and preventive health services. The company said in-home services reduce barriers to care by providing patients with convenient access to high-value care to improve health outcomes.
Signify Health is a healthcare platform that uses advanced analytics, technology and nationwide healthcare provider networks to create and power value-based payment programs. Last month, CVS Health announced that it would acquire Signify Health for $8 billion in an effort to move more care into the home and expand its value-based care opportunities.